Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenograftsGaspar J. Kitange, Jann N. Sarkaria, Brett L. Carlson et al.|Neuro-Oncology|2008Cited by 387
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177Paul D. Brown, Jan C. Buckner, Robert B. Jenkins et al.|Journal of Clinical Oncology|2008Cited by 275
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panelJann N. Sarkaria, C. David James, Lin Yang et al.|Molecular Cancer Therapeutics|2007Cited by 203
Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma XenograftsGaspar J. Kitange, Jann N. Sarkaria, Ann C. Mladek et al.|Clinical Cancer Research|2012Cited by 151
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft modelGaspar J. Kitange, Jann N. Sarkaria, Brett L. Carlson et al.|Journal of Neuro-Oncology|2008Cited by 97